XML 48 R27.htm IDEA: XBRL DOCUMENT v3.6.0.2
BUSINESS SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:
 
 
2016
 
2015
 
2014
McKesson Corporation
 
22
%
 
21
%
 
20
%
AmerisourceBergen Corporation
 
18
%
 
16
%
 
17
%
Cardinal Health, Inc.
 
14
%
 
12
%
 
12
%
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
Selected geographic area information was as follows:
 
 
Revenues
 
Property, Plant and Equipment
Dollars in Millions
 
2016
 
2015
 
2014
 
2016
 
2015
United States
 
$
10,720

 
$
8,188

 
$
7,716

 
$
3,865

 
$
3,681

Europe
 
4,215

 
3,491

 
3,592

 
1,003

 
616

Rest of the World(a)
 
3,964

 
4,142

 
3,459

 
112

 
115

Other(b) 
 
528

 
739

 
1,112

 
—

 
—

Total
 
$
19,427

 
$
16,560

 
$
15,879

 
$
4,980

 
$
4,412

(a)
Includes Japan which represented 7%, 10% and 6% of total revenues in 2016, 2015 and 2014, respectively.
(b)
Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
Schedule of Revenue from External Customers by Products and Services [Table Text Block]
The composition of total revenues was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2016
 
2015
 
2014
Net product sales
 
$
17,702

 
$
14,045

 
$
11,660

Alliance revenues
 
1,629

 
2,408

 
3,828

Other revenues
 
96

 
107

 
391

Total Revenues
 
$
19,427

 
$
16,560

 
$
15,879

Product revenues were as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2016
 
2015
 
2014
Oncology
 
 
 
 
 
 
Empliciti (elotuzumab)
 
$
150

 
$
3

 
$
—

Erbitux* (cetuximab)
 
—

 
501

 
723

Opdivo (nivolumab)
 
3,774

 
942

 
6

Sprycel (dasatinib)
 
1,824

 
1,620

 
1,493

Yervoy (ipilimumab)
 
1,053

 
1,126

 
1,308

Cardiovascular
 
 
 
 
 
 
Eliquis (apixaban)
 
3,343

 
1,860

 
774

Immunoscience
 
 
 
 
 
 
Orencia (abatacept)
 
2,265

 
1,885

 
1,652

Virology
 
 
 
 
 
 
Baraclude (entecavir)
 
1,192

 
1,312

 
1,441

Hepatitis C Franchise
 
1,578

 
1,603

 
256

Reyataz (atazanavir sulfate) Franchise
 
912

 
1,139

 
1,362

Sustiva (efavirenz) Franchise
 
1,065

 
1,252

 
1,444

Neuroscience
 
 
 
 
 
 
Abilify* (aripiprazole)
 
128

 
746

 
2,020

Mature Products and All Other
 
2,143

 
2,571

 
3,400

Total Revenues
 
$
19,427

 
$
16,560

 
$
15,879